Lexeo Therapeutics, Inc. Common Stock

NASDAQ: LXEO · Healthcare · Biotechnology

PublicHQ New York City, CIK 0001907108Reports USD

#900 of 1,394 Healthcare companies by revenue

EA Score

35D

FH 43DQ 21GM —SS 46

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$100.0M

Employees

Market cap

$368.3M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$654.0k$654.0k2023

Net income-$100.0M-$100.0M2025

Operating income-$109.3M-$109.3M2025

Total assets$268.7M$268.7M2025

Liabilities$22.0M$22.0M2025

Equity$246.7M$246.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Lexeo Therapeutics, Inc. Common Stock booked $654.0k in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -15284.6% net margin.

Peers · Healthcare

Elite Pharmaceuticals, Inc.77B+Simulations Plus, Inc.69B Abeona Therapeutics Inc.68B Palisade Bio, Inc.70B

Key facts

CEOR. Nolan Townsend

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, null

ExchangeNASDAQ: LXEO

Employees75

IPO date2023-11-03

Latest filings

8-K2026-06-29 8-K2026-06-15 10-Q2026-05-11 8-K2026-05-11 DEF 14A2026-04-30 8-K2026-04-30 8-K2026-03-30 10-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.